[go: up one dir, main page]

MD1780G2 - Method of treatment of patients with hepatic cirrhosis - Google Patents

Method of treatment of patients with hepatic cirrhosis Download PDF

Info

Publication number
MD1780G2
MD1780G2 MDA20010032A MD20010032A MD1780G2 MD 1780 G2 MD1780 G2 MD 1780G2 MD A20010032 A MDA20010032 A MD A20010032A MD 20010032 A MD20010032 A MD 20010032A MD 1780 G2 MD1780 G2 MD 1780G2
Authority
MD
Moldova
Prior art keywords
patients
hepatic cirrhosis
treatment
hepatoprotectors
losartan
Prior art date
Application number
MDA20010032A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD1780F1 (en
Inventor
Влада-Татьяна ДУМБРАВА
Eugen Tcaciuc
Original Assignee
Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова filed Critical Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова
Priority to MDA20010032A priority Critical patent/MD1780G2/en
Publication of MD1780F1 publication Critical patent/MD1780F1/en
Publication of MD1780G2 publication Critical patent/MD1780G2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to medicine, namely to hepatology.Summary of the invention consists in that concomitantly with the administration of hepatoprotectors and vitamins, the patients with hepatic cirrhosis are additionally administered during 27…35 days losartan for 0,0125…0,025 g one time a day per os.
MDA20010032A 2001-02-02 2001-02-02 Method of treatment of patients with hepatic cirrhosis MD1780G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20010032A MD1780G2 (en) 2001-02-02 2001-02-02 Method of treatment of patients with hepatic cirrhosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20010032A MD1780G2 (en) 2001-02-02 2001-02-02 Method of treatment of patients with hepatic cirrhosis

Publications (2)

Publication Number Publication Date
MD1780F1 MD1780F1 (en) 2001-11-30
MD1780G2 true MD1780G2 (en) 2002-05-31

Family

ID=19739746

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20010032A MD1780G2 (en) 2001-02-02 2001-02-02 Method of treatment of patients with hepatic cirrhosis

Country Status (1)

Country Link
MD (1) MD1780G2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4458C1 (en) * 2014-06-19 2017-08-31 Мария ДАНУ Use of Polybiolin drug in patients with liver cirrhosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lebrec D. et al. A randomized controller study of propranolol for prevention of recurrent gastruintestinal bleeding in patients with cirrhosis: a final report. Hepatology, 1984, vol. 4, p. 355-358 *
Ohnishi A. et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clinical Pharmacology and Therapeutics, 1989, vol. 45, p. 657-665 *

Also Published As

Publication number Publication date
MD1780F1 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
DK0502092T3 (en) Oral preparation for the treatment of inflammatory bowel diseases
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
DE69831869D1 (en) IMPROVED ADMINISTRATION TECHNIQUE FOR MULTIPLE MEDICAMENTALS
MXPA03006217A (en) Spaced drug delivery system.
CY1105707T1 (en) COMBINATIONS OF FORMOTEROL AND A TRIOTROP SALT
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
BRPI0406858A (en) Controlled release of highly soluble agents
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
MD990258A (en) Method of treatment of the acute viral hepatitis B
MXPA04001912A (en) Novel aminobenzoephenones.
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
MD1780G2 (en) Method of treatment of patients with hepatic cirrhosis
SE9800905D0 (en) New therapy in glomerulonephritis
GB0018322D0 (en) Pharmaceutical compositions
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
MD1609F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
MD1610G2 (en) Method of the recidivating chronic aphthous stomatitis treatment
MD3381G2 (en) Method of treating the chronic parotitis to children
MD1469G2 (en) Method of treatment of the burn shock